22
Participants
Start Date
June 30, 2020
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2026
Candonilimab and ATRA
Candonilimab at a dose of 6mg/kg IV Q3W will be administered until a maximum treatment duration of 1 year. All-trans retinoic acid will be administered at a dose of 25mg/m² twice daily on days 1-14, with a treatment cycle of 21 days, until a maximum treatment duration of 6 months, or until the occurrence of oral cancer or other malignancies, death, intolerable toxicity, withdrawal of informed consent, or any other reasons specified in the protocol.
other treatment or observation
other treatment other than Candonilimab/ATRA or observation
Shanghai Ninth People's Hospital, Shanghai
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
OTHER